Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications
Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition.
Journal: Skin therapy letter
Published: May 27, 2026
A Review of Post-Inflammatory Pigmentation Changes: Pathophysiology, Diagnosis and Treatment.
Journal: Journal of cutaneous medicine and surgery
Published: March 18, 2026
Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.
Journal: Lancet (London, England)
Published: March 06, 2026
MASCC clinical practice statement: Prevention and management of acute radiation dermatitis using topical corticosteroids.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: February 25, 2026
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.
Journal: The British journal of dermatology
Published: January 30, 2026
Response to Reader Comment on: Navigating Bullous Pemphigoid: Consensus Recommendations for Diagnosis and Management-A Canadian Perspective.
Journal: Journal of cutaneous medicine and surgery
Published: December 27, 2025
A Response to the Letter to the Editor: "Comment on COCOON: Daily 4% Chlorhexidine for Nail Care-Rationale, Safety, and Evidence Gaps".
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 05, 2025
Massive Solitary Liver Metastasis From a Locally Recurrent Basal Cell Carcinoma Treated With Stereotactic Body Radiation Therapy: A Rare Manifestation of a Common Disease.
Journal: Advances in radiation oncology
Published: November 03, 2025
52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: October 28, 2025
Glucagon-like peptide-1 receptor agonists as metabolic adjuncts in immune-mediated skin disease.
Journal: Journal of the American Academy of Dermatology
Published: October 11, 2025
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: October 10, 2025
Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib.
Journal: Skin therapy letter
Published: September 24, 2025
Last Updated: 09/26/2026